PremiumThe FlyVeru reports Q1 cont-op EPS (1c) vs. (8c) last year Largest borrow rate increases among liquid names Veru’s enobosarm meets primary endpoint in Phase 2b weight reduction trial PremiumThe FlyVeru announces meta-analysis presentation at ObesityWeek on enobosarm Veru Ends Sales Agreement with Jefferies, Halts Stock Sales Veru Inc Reported Earnings. Did it Beat Estimates? PremiumThe FlyVeru announces safety, body composition data from presentations at ADA Veru management to meet virtually with B. Riley Veru announces Heymsfield as Principal Investigator for Phase 2b trial